<?xml version="1.0" encoding="UTF-8"?>
<p id="par0260">Currently, IFN-a therapy is classified as category C during pregnancy, as it appears to be linked to abortive effect in animal models, such as the rhesus monkey [
 <xref rid="bib0685" ref-type="bibr">137</xref>], the drug also interferes in the fertility degree, and the menstrual cycle that normalize after discontinuing treatment. In addition, serum estradiol and progesterone levels were decreased in women treated with IFN [
 <xref rid="bib0690" ref-type="bibr">138</xref>]. However, IFN-a is used in pregnant women with thrombocytopenia [
 <xref rid="bib0695" ref-type="bibr">139</xref>] and also was used as an alternative to BCR-GLA-positive leukemia treatment in pregnant women, with no evidence of increases to the rate of congenital anomalies or spontaneous abortions was found [
 <xref rid="bib0700" ref-type="bibr">140</xref>].
</p>
